Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3365
Structure:
Synonyms:
.alpha.-(2,4-Difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol
1H-1,2,4-Triazole-1-ethanol,
1H-1,2,4-Triazole-1-ethanol, .alpha.-(2,4-difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-
1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
86386-73-4
AbZ Brand of Fluconazole
Afungil
AIDS-000315
AIDS-010197
AIDS-010227
AIDS-093051
AIDS-110399
AIDS-110400
AIDS-110401
AIDS-112166
AIDS-121430
AIDS000315
AIDS010197
AIDS010227
AIDS093051
AIDS110399
AIDS110400
AIDS110401
AIDS112166
AIDS121430
Alflucoz
Aliud Brand of Fluconazole
alpha-(2,4-Difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol
ALPHA-(2,4-DIFLUOROPHENYL)-ALPHA-(1H-1,2,4-TRIAZOLE-1-YLMETHYL)-1H-1,2,4-TRIAZOLE-1-ETHANOL
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
B?agyne
Baten
BB_SC-4645
betapharm Brand of Fluconazole
Biocanol
Biozolene
BSPBio_003504
C13H12F2N6O
Canzol
CCRIS 7211
CHEBI:46081
Chemia Brand of Fluconazole
Cryptal
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
D00322
D015725
DB00196
Diflazon
Diflucan
Diflucan (TN)
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Dimycon
DivK1c_001030
DRG-0005
Effik Brand of Fluconazole
Elazor
F8929_SIGMA
FCZ
FLC
FLCZ
FLU
Fluc Hexal
Flucazol
Flucobeta
FlucoLich
Fluconazol
Fluconazol AbZ
Fluconazol AL
Fluconazol Isis
Fluconazol ratiopharm
Fluconazol Stada
Fluconazol von ct
Fluconazol [Spanish]
Fluconazol-Isis
Fluconazol-ratiopharm
FLUCONAZOLE
Fluconazole & Bovine Lactoferrin
Fluconazole & hGCSF
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:BAN:INN:JAN]
Fluconazole [USAN:INN:BAN:JAN]
Fluconazolum
Fluconazolum [Latin]
Flucostat
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Flusol
Fluzone
FLZ
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
Hexal Brand of Fluconazole
HSDB 7420
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
LS-1858
Mack Brand of Fluconazole
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-03
NCGC00095089-04
NCGC00095089-05
nchembio.100-comp3
nchembio.65-comp15
Neofomiral
NINDS_001030
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
ratiopharm Brand of Fluconazole
SAT Brand of Fluconazole
Silanes Brand of Fluconazole
SMR000471882
Solacap
SPBio_001613
SPECTRUM1503975
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
Zemyc
ZINC00004009
Zoltec
Zonal
ATC-Codes:
Side-Effects:
Side-EffectFrequency
alcohol abuse0.0010
hypokalemia0.0010
jaundice0.0010
leukopenia0.0010
melena0.0010
nausea0.0010
neutropenia0.0010
pruritus0.0010
seizures0.0010
stevens - johnson syndrome0.0010
thrombocytopenia0.0010
urticaria0.0010
vomiting0.0010
hepatic failure0.0010
hypertriglyceridemia0.0010
hypercholesterolemia0.0010
hepatitis0.0010
abdominal pain0.0010
agranulocytosis0.0010
alopecia0.0010
anaphylaxis0.0010
angioedema0.0010
diarrhea0.0010
dizziness0.0010
dyspepsia0.0010
bleeding0.0010
hematuria0.0010
gastrointestinal bleeding0.0010
epistaxis0.0010
toxic epidermal necrolysis0.0010
edema0.0010
vertigo0
cancer0
constipation0
hepatic necrosis0
myalgia0
tremor0
anorexia0
malaise0
somnolence0
convulsions0
insomnia0
rash0
paresthesia0
fever0
flatulence0
asthenia0
dry mouth0
anemia0
fatigue0
increased sweating0
allergic reaction0

Target

show target details
Uniprot ID:CP1A2_HUMAN
Synonyms:
CYPIA2
Cytochrome P450 1A2
P(3)450
P450 4
P450-P3
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2HI4
Structure:
2HI4

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----
----

References:

10952477
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.. T Kantola; J T Backman; M Niemi; K T Kivist÷; P J Neuvonen (2000) European journal of clinical pharmacology display abstract
OBJECTIVE: To study the effects of fluconazole on the pharmacokinetics of fluvastatin and pravastatin, two inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. METHODS: Two separate randomised, double-blind, two-phase, crossover studies with identical study design were carried out. In each study, 12 healthy volunteers were given a 4-day pretreatment with oral fluconazole (400 mg on day 1 and 200 mg on days 2-4) or placebo, according to a randomisation schedule. On day 4, a single oral dose of 40 mg fluvastatin (study I) or 40 mg pravastatin (study II) was administered orally. Plasma concentrations of fluvastatin, pravastatin and fluconazole were measured over 24 h. RESULTS: In study 1, fluconazole increased the mean area under the plasma fluvastatin concentration-time curve (AUC0-infinity) by 84% (P < 0.01), the mean elimination half-life (t1/2) of fluvastatin by 80% (P < 0.01) and its mean peak plasma concentration (Cmax) by 44% (P < 0.05). In study II, fluconazole had no significant effect on the pharmacokinetics of pravastatin. CONCLUSIONS: Fluconazole has a significant interaction with fluvastatin. The mechanism of the increased plasma concentrations and prolonged elimination of fluvastatin is probably inhibition of the CYP2C9-mediated metabolism of fluvastatin by fluconazole. Care should be taken if fluconazole or other potent inhibitors of CYP2C9 are prescribed to patients using fluvastatin. However, pravastatin is not susceptible to interactions with fluconazole or other potent CYP2C9 inhibitors.
9551703
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.. K M Kaukonen; K T Olkkola; P J Neuvonen (1998) European journal of clinical pharmacology display abstract
OBJECTIVE: Losartan is metabolised to its active metabolite E-3174 by CYP2C9 and CYP3A4 in vitro. Itraconazole is an inhibitor of CYP3A4, whereas fluconazole affects CYP2C9 more than CYP3A4. We wanted to study the possible interaction of these antimycotics with losartan in healthy volunteers. METHODS: A randomised, double-blind, three-phase crossover study design was used. Eleven healthy volunteers ingested orally, once a day for 4 days, either itraconazole 200 mg, fluconazole (400 mg on day 1 and 200 mg on days 2-4) or placebo (control). On day 4, a single 50-mg oral dose of losartan was ingested. Plasma concentrations of losartan, E-3174, itraconazole, hydroxy-itraconazole and fluconazole were determined over 24 h. The blood pressure and heart rate were also recorded over 24 h. RESULTS: The mean peak plasma concentration (Cmax) and area under the curve [AUC(0-infinity)] of E-3174 were significantly decreased by fluconazole to 30% and to 47% of their control values, respectively, and the t1/2 was increased to 167%. Fluconazole caused only a nonsignificant increase (23-41%) in the AUC and t1/2 of the unchanged losartan. Itraconazole had no significant effect on the pharmacokinetic variables of losartan or E-3174. The ratio AUC(0-infinity)(E-3174)/AUC(0-infinity)losartan was 60% smaller during the fluconazole than during the placebo and itraconazole phases. No clinically significant changes in the effects of losartan on blood pressure and heart rate were observed between fluconazole, itraconazole and placebo phases. CONCLUSION: Fluconazole but not itraconazole interacts with losartan by inhibiting its metabolism to the active metabolite E-3174. This implicates that, in man, CYP2C9 is a major enzyme for the formation of E-3174 from losartan. The clinical significance of the fluconazole losartan interaction is unclear, but the possibility of a decreased therapeutic effect of losartan should be kept in mind.
9929500
Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.. M A Gibbs; K E Thummel; D D Shen; K L Kunze (1999) Drug metabolism and disposition: the biological fate of chemicals display abstract
The purpose of this study was to compare the kinetics of intestinal and hepatic cytochrome P-450 3A (CYP3A) inhibition by using microsomal midazolam 1'-hydroxylation as a marker of enzyme activity. The effect of two antifungal agents commonly implicated in CYP3A drug-drug interactions was examined. Inhibition type and affinities were determined for human liver and intestinal microsomes screened for the presence or absence of CYP3A4 and CYP3A5, as well as for cDNA-expressed CYP3A4 and CYP3A5 microsomes. Ketoconazole and fluconazole were found to be noncompetitive inhibitors of both enzymes. Ketoconazole exhibited a Ki for cDNA-expressed CYP3A4 of 26. 7 +/- 1.71 nM, whereas the Ki for cDNA expressed CYP3A5 was 109 +/- 19.7 nM. Corresponding Ki values for fluconazole were 9.21 +/- 0.51 microM and 84.6 +/- 12.9 microM. For liver and intestinal microsomes that contained only CYP3A4, the average ketoconazole Ki was found to be 14.9 +/- 6.7 nM and 17.0 +/- 7.9 nM, respectively, whereas fluconazole yielded mean respective Ki values of 10.7 +/- 4.2 microM and 10.4 +/- 2.9 microM. Liver and intestinal microsomes that contained an equal or greater amount of CYP3A5, in addition to CYP3A4, were less susceptible to inhibition by both ketoconazole and fluconazole. These findings suggest that there can be significant differences in the affinity of these two enzymes for inhibitors. This may further broaden interindividual variability with respect to the magnitude of in vivo drug-drug interactions. We also conclude that there is no significant difference in inhibition type and affinity of ketoconazole and fluconazole for hepatic versus intestinal CYP3A4.
SuperCyp